New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 15, 2014
06:17 EDTACURAcura announces preliminary discussions held with FDA for acetaminophen tablet
Acura Pharmaceuticals announced preliminary discussions from a meeting held with the FDA regarding the development pathway for Acura's AVERSION hydrocodone with acetaminophen tablet development candidate, which is intended to provide abuse-deterrent features to address abuse by nasal snorting and injection. In a May 2014 letter to Acura, FDA questioned the relevance of abuse of hydrocodone with acetaminophen products by nasal snorting after reviewing clinical and epidemiology data submitted by Acura. The FDA continues to question the relevance of abuse of hydrocodone with acetaminophen products by the intranasal route of administration and suggested additional information may help better inform their decision. The FDA indicated in the discussions that Acura may conduct an additional nasal abuse liability study for its AVERSION hydrocodone with acetaminophen product candidate, the outcomes of which may help inform the relevance decision as well as establish a reduction in drug liking, which was not statistically significant in an earlier Acura study. The FDA requested further time to deliberate on the issues discussed during the meeting before issuing final meeting minutes. Acura intends to review its clinical data from Study AP-ADF-301 to determine whether to proceed with an additional clinical study for its AVERSION hydrocodone with acetaminophen product candidate and to further evaluate options to address the issues of intranasal abuse and drug liking raised by the FDA.
News For ACUR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 1, 2015
06:17 EDTACURAcura Pharma to raise about $7.6M from certain institutional investors
Acura Pharmaceuticals announced it has entered into a Securities Purchase Agreement with certain institutional investors to sell 9.79M shares of common stock at a price of 78c per share, payable at closing. Roth Capital Partners served as sole placement agent for the offering. After placement agent fees and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately $7.05M. The offering is expected to close on or about July 7, subject to customary closing conditions. The company intends to use the net proceeds from the offering for general corporate purposes, funding product development and for general and administrative expenses.
June 29, 2015
06:19 EDTACURAcura Pharma receives Notice of Allowance from USPTO for LIMITX
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use